WIN Symposium 2014: WINning combinations for precision cancer medicine
12 Sep 2013
Breakthrough biomarker investigations and combined approaches
In this WIN 2014 newsletter:
Save the dates for WIN 2014
Hot topics at WIN 2014
WIN Consortium announces the WIN Symposium 2014
Marriott Rive Gauche, Paris, June 23-24, 2014
An exceptional event entirely dedicated to breakthrough biomarker investigations and combined therapeutic approaches:
“This original theme is for the first time the subject of an international symposium”, said Dr. Vladimir Lazar, Chief Operating Officer of WIN Consortium. “Join the world’s leaders in precision cancer medicine, Leroy Hood, Richard L. Schilsky, Razelle Kurzrock, Jean-Charles Soria and many others”
“Most patients’ tumors are driven by multiple molecular aberrations that cannot be controlled by a single targeted agent. The challenge is to identify and test smart combinations of targeted agents capable of blocking optimal pathways at the same time”, said John Mendelsohn, Chair of the WIN consortium.
Pr. Alexander Eggermont, Vice-Chair of WIN consortium and co-chair of the WIN 2014 symposium stated: “Some combinations are currently under investigation. Results of these and additional clinical studies are eagerly awaited as they hold the promise of taking precision cancer medicine to the next level.”
Hot topics at WIN 2014
“Winning combinations for precision cancer medicine”
Breakthrough biomarker investigations and combined therapeutic approaches
Molecular analysis of immune cells and immunotherapy
What can we learn from hemato-oncology?
Tumor cells plasticity and druggable targets
Combination of targeted therapies
New findings in fundamental mechanisms in pediatric solid and liquid cancers
Keynote Lecturers include: René Bernards, Jerome Galon, and Bob Löwenberg
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023